Pharmaceutical and healthcare market in Poland 2011

Report overview

The report provides information on the size of the pharmaceutical market in Poland (pharmacy and hospital markets) in 2002-2010 as well as forecasts of market size for 2011-2013. The data is also segmented by:

• domestic and foreign preparations
• refunded and fully non-refundable preparations
• innovative and generic drugs
• 12 ATC categories.

The report is supplemented by an analysis of the drug refund system in Poland: how the system works, how much is spent on drug reimbursement, along with an analysis of the most recent changes in drug reimbursement lists and of provisions planned in a number of regulations currently being prepared by the Health Ministry, with the Reimbursement Act at the helm.
The overview of the pharmaceutical market is augmented by the most recent information on the healthcare market in Poland, e.g. economic data, headcount information, healthcare system organisation.

Why this report?

• We are a leader on the market of information about the pharmaceutical sector and this publication represents a key product in our portfolio.
• The report contains key data and development forecasts valuable to every pharmaceutical firm active in Poland.
• The market will slow down, and companies active on it will face an increasingly difficult situation - which will force them to review their business strategies for the near future, with our report as an excellent point of reference.
• The Reimbursement Act, which is to come into force, will introduce many changes in the market - all are discussed in the report.
• The possibility of the introduction of supplemental healthcare insurance creates an opportunity of dental care insurance.
• Additional opportunities are also being created under the currently in the works European directive “ Patients without borders ”, which will make it easier to provide services to EU citizens outside of their home countries, and will mean the end of the monopoly of the National Health Fund for the contracting of medical services.

Main topics covered in the report:

• Value and development forecasts for 2010-2013 for the Polish pharmaceutical market.
• Discussion of the different drug categories, domestic and foreign drugs, inpatient and outpatient markets, refunded drugs, ATC categories, in particular from the perspective of innovative and generic drugs.
• Overview of the situation in Poland – key trends.
• Detailed description of how the drug reimbursement system works in Poland, including a discussion of planned changes, also in the pharmacy segment.
• Presentation of key players as well as best selling preparations.
• Description of healthcare system in Poland and key information about the system.

What questions does the report answer?

• What are the development prospects of the pharmaceutical market in Poland?
• Which sector is the most attractive from the perspective of future revenue potential? Innovative or generic drugs? Inpatient or outpatient segment?
• Is the market conductive to the success of domestic companies or foreign players?
• Which ATC categories will develop the most rapidly and which ones the least?
• What are the key trends on the market and what is likely to happen in the near future?
• What is the procedure for applying for reimbursement?
• What changes in procedures/system/refund policies and price setting can be expected in the near future in Poland?
• How is health care organised in Poland?

When will the report be useful?

• commencing operations in Poland
• entering the market
• engaging in business on the market
• expanding operations
• looking for information on the Polish market and its segments
• looking for an analysis of the reimbursement system
• seeking an estimate of the value of the segments and their development forecasts
• assessing the possibility of reimbursement
• developing a strategy of launching a new product also on the Polish market
• planning strategic development of a company in particular in the area of refunded drugs 

Extract from this report

• In 2010 sales of generic pharmaceuticals (in particular those manufactured by foreign pharma makers) rose slightly more quickly than the overall innovative drugs market. Though the global financial crisis did not materially impact the Polish pharmaceuticals market, last year both patients and doctors were more apt to opt for cheaper generics rather than innovative preparations.
• In line with our forecasts, the hospital market, which to a great extent is dependent on public subsidies, will stagnate because of anticipated restrictions on state expenditure on drug reimbursement.

Market commentary by expert

According to our forecasts, the pharmaceutical market in Poland will exceed PLN 31bn (approximately €8bn) in 2011, growing by 4% compared with 2010. Generally we expect that the “years of plenty” for the pharmaceutical market are over and that this situation will last for a few years. The main reason are the anticipated cuts in public spending on reimbursed medicines, which constitute a substantial part of the market. Patients will probably have to pay more, and not all will be able to afford the extra burden. Some will be forced to refrain from buying more expensive or less important medicines. Also, we do not expect many new innovative drugs to be introduced into reimbursement lists, something that would support the sales of these expensive medicines.
 
Monika Stefańczyk, Head Pharmaceutical Market Analyst

Request sample pages/interactive screenshare

To receive more information on this report, please sign up.

*required

*Would you like a FREE interactive screenshare?		Yes No
*Email:
		To make sure you receive the requested information, add info@pmrcorporate.com to your company trusted emails. Contact your IT department for details.
*Your company core business:		IT, Telecoms Construction Pharma, Healthcare Retail, FMCG Finance, Investments, Banking Consulting, Research, Law Government, Trade Organisations Media, Publications Education, Students Other
		Privacy Policy
		I agree with terms and conditions of PMR Privacy Policy. SUBSCRIBE

1. Report methodology p. 9

2. Executive summary p. 13

3. Overview of the pharmaceutical market in Poland p. 19

   • Main trends and events on drug market p. 19
     • Main past trends and events p. 19
     • Main anticipated trends and events p. 21
   • Market introduction p. 23
   • Market value p. 24
     • Total pharmaceutical market p. 24
     • Pharmacy market p. 25
       • By value p. 25
       • By volume p. 28
   • Hospital market p. 28
   • Generic and innovative drugs p. 29
     • Market value p. 29
     • Share of pharmaceutical market p. 30
   • Domestic and foreign drugs p. 32
     • Market value p. 32
     • Share of pharmaceutical market p. 33
   • Drug prices p. 35
     • Margins p. 37

4. Pharmacy market by therapeutic groups p. 41

   • Alimentary tract and metabolism p. 43
   • Cardiovascular system p. 44
   • Central nervous system p. 45
   • Respiratory system p. 46
   • Musculo-skeletal system p. 47
   • Genito-urinary system p. 47
   • Anti-infectives p. 48
   • Blood and blood forming organs p. 49
   • Dermatologicals p. 50
   • Antineoplastic and immunomodulating agents p. 51
   • Sensory organs p. 52
   • Systemic hormonal preparations p. 53
   • Parasitology p. 54

5. Best selling drugs p. 55

   • Patents and regulatory issues p. 57

6. Pharmaceutical companies in Poland p. 59

   • Leading players in the total market p. 60
   • Leading domestic players p. 61
   • Major events associated with manufacturers p. 62

7. Pricing p. 67

   • Principles p. 67
   • Process p. 68
     • Medicines Management Team/Economic Commission p. 69
     • Agency for Medical Technology Evaluations p. 70
     • Reference pricing p. 71
       • External reference pricing p. 71
       • Internal reference pricing p. 71
     • Outcome p. 74
     • Price revision p. 74
   • Generic pricing p. 74
   • Prices and margins p. 76
     • VAT rate p. 76
     • Non-reimbursed drugs on pharmacy market p. 76
       • Reimbursed drugs on pharmacy market p. 76
       • Drugs on hospital market p. 77

8. Reimbursement p. 81

   • Patient co-payment p. 81
     • Pharmacy market p. 81
       • Generic substitution p. 83
     • Hospital market p. 83
   • Classification p. 83
     • General (open) reimbursement p. 84
     • Chronic disease treatments p. 85
   • Market breakdown p. 85
   • Discounts p. 88
   • Hospital segment p. 89
     • Financing p. 89
     • Drug selection p. 89
     • Procurement p. 90
     • Distribution p. 90
   • Reimbursement spending p. 90
     • Open reimbursement p. 90
     • Therapeutic programmes p. 91
     • Chemotherapy p. 95
   • Off-label use p. 96
   • Revision of reimbursement list p. 96
     • Addition of new products p. 97
     • Latest changes to reimbursement lists p. 99
       • December 2010 listing p. 99
       • December 2009 listing p. 99
       • March 2009 listing p. 100
     • Controversies p. 101
     • Expected changes to reimbursement p. 101
   • Prescribing controls p. 103
   • Reimbursement reform p. 104
     • Timelines and progress of work p. 104
     • The key proposed changes p. 104
     • Consequences p. 106
     • Comments on the measures p. 108
       • Transparency p. 108
       • Risk-sharing agreements p. 109
       • Change in distribution mark-ups/fixed public price p. 109
       • Tax on manufacturers p. 110

9. Distribution p. 111

   • Wholesale distribution p. 111
     • Segment profile p. 111
     • Profiles of selected key players p. 112
   • Pharmacy distribution p. 124
     • Segment overview p. 124
       • Legal environment p. 124
       • The number of pharmacies p. 124
       • The financial standing of pharmacies p. 125
       • Pharmacy chains p. 125
     • Profiles of selected key players p. 126
   • Non-pharmacy distribution p. 131
     • Wholesalers p. 131
     • General stores p. 131
   • Online distribution p. 132
     • Legal environment p. 132
     • Internet pharmacies p. 133

10. Healthcare market in Poland p. 135

    • Basic features of the Polish health care system p. 135
    • Data on healthcare in Poland p. 136

11. List of graphs p. 153

12. List of tables p. 157

13. About PMR p. 159

14. Contact PMR p. 160

List of graphs

1. Value (PLN bn) and growth in pharmaceutical market in Poland, 2007-2013
2. Value (PLN bn) and growth in pharmacy market in Poland, 2007-2013
3. Value (PLN bn) and change in hospital drug market in Poland, 2007-2013
4. CAGR for main ATC categories in Poland, 2011-2013
5. Value (PLN bn) and growth in pharmaceutical market in Poland, 2002-2010
6. Percentage shares of individual segments of the pharmaceutical market in Poland, March 2009-April 2010
7. Value (PLN bn) and growth in pharmaceutical market in Poland, 2007-2013
8. Value (PLN bn) and growth in pharmacy market in Poland, 2007-2013
9. Percentage shares of individual segments of the pharmacy market in Poland, 2010
10. Value (€ bn) of the pharmaceutical market in Poland in comparison to other European countries, Q2 2009-Q1 2010
11. Value (€) of pharmaceutical spending per capita in Poland in comparison to other European countries, Q2 2009-Q1 2010
12. Volume (standard units) of pharmaceutical market in Poland in comparison to other European countries, Q2 2009-Q1 2010
13. Value (PLN bn) and change in hospital drug market in Poland, 2007-2013
14. Value (€ bn) and y-o-y change in the Polish generic drugs market, 2007-2013
15. Value (€ bn) and y-o-y change in the Polish innovative drugs market, 2007-2013
16. Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Poland, by value, Q2 2009-Q1 2010
17. Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Poland, by volume, Q2 2009-Q1 2010
18. Share of generic and innovative drugs as a proportion of Rx pharmaceutical market in Poland, by value, 2004-Q1 2010
19. Share of generic and innovative drugs as a proportion of Rx pharmacy market in Poland, by volume, 2004-Q1 2010
20. Value (PLN bn) and increase in sales of foreign medicines in Poland, 2000-2010
21. Value (PLN bn) and increase in sales of domestic medicines in Poland, 2000-2010
22. Share of Polish and foreign drugs as a proportion of the Rx pharmaceutical market, by value, Q3 2005-Q1 2010
23. Share of Polish and foreign drugs as a proportion of the Rx pharmaceutical market, by volume, Q2 2005-Q4 2009
24. Average drug prices on pharmacy market in Poland (PLN), 2002-2010
25. Shares of selected drug price groups in total turnover of pharmacies in Poland, 2007 and 2010
26. Average price per standard drug unit (€) of in Poland in comparison to other European countries, Q2 2009-Q1 2010
27. European countries with the lowest prices for generic drugs (€), March 2011
28. European countries with the lowest prices for innovative drugs (€), March 2011
29. Average margins on pharmacy market and y-o-y change in Poland, 2007-2010
30. Average margins on reimbursed drugs and y-o-y change in Poland, 2007-2010
31. Average margins on non-reimbursed products and y-o-y change in Poland, 2005-2010
32. Pharmacy market by ATC categories in Poland, in value terms, 2009
33. Pharmacy market by ATC categories in Poland, in value terms, 2010
34. Sales value (PLN m) and y-o-y change of drugs used in alimentary tract and metabolic diseases in Poland, 2002-2013
35. Sales value (PLN m) and y-o-y change of drugs used in cardiovascular diseases in Poland, 2002-2013
36. Sales value (PLN m) and y-o-y change of drugs used in central nervous system in Poland, 2002-2013
37. Sales value (PLN m) and y-o-y change of drugs used in respiratory system in Poland, 2002-2013
38. Sales value (PLN m) and y-o-y change of drugs used in musculo-skeletal system in Poland, 2002-2013
39. Sales value (PLN m) and y-o-y change of drugs affecting genito-urinary system in Poland, 2002-2013
40. Sales value (PLN m) and y-o-y change of anti-infectives in Poland, 2002-2013
41. Sales value (PLN m) and y-o-y change of drugs used in diseases of the blood and blood forming organs in Poland, 2002-2013
42. Incidence of deep vein thrombosis in Poland (‘000), 2005-2010
43. Sales value (PLN m) and y-o-y change of dermatologicals in Poland, 2002-2013
44. Sales value (PLN m) and y-o-y change of antineoplastic and immunomodulating agents in Poland, 2002-2013
45. Incidence of neoplasms in Poland (‘000), 2000-2010
46. Sales value (PLN m) and y-o-y change of drugs used in disorders of sensory organs in Poland, 2002-2013
47. Number of patients with glaucoma in Poland (‘000), 2001-2010
48. Sales value (PLN m) and y-o-y change of systemic hormonal preparations in Poland, 2002-2013
49. Sales value (PLN m) and y-o-y change of parasitology drugs in Poland, 2002-2013
50. The number of players in the pharmaceutical market in Poland in comparison to other European countries, Q2 2009-Q1 2010
51. Top 10 Polish pharmaceutical companies, by value ($ m), July 2009-June 2010
52. Top 10 Polish pharmaceutical companies, by volume (million pieces), July 2009-June 2010
53. Patient and state co-payment for drugs on pharmacy market in Poland, 2007 – January-February 2011
54. Patient and state co-payment for reimbursed drugs on pharmacy market in Poland, January 2009-February 2011
55. Breakdown of market by co-payment type in Poland, from the point of view of state (reimbursement), 2010
56. Breakdown of market by co-payment type in Poland, from the point of view of patient, 2010
57. Breakdown of market by co-payment type in Poland, from the point of view of state (reimbursement), by value, 2009
58. Breakdown of market by co-payment type in Poland, from the point of view of state (reimbursement), by volume, 2009
59. NFZ spending on drug reimbursement and y-o-y change in Poland (PLN m), 2003-2011
60. The drug substances used in therapeutic programmes generating the highest cost for NFZ in Poland (PLN m), 2009
61. Share of NFZ’s expenditures on therapeutic programmes in Poland, by condition, 2009
62. NFZ spending on drug therapy programmes and y-o-y change in Poland (PLN m), 2005-2011
63. Ten most costly chemotherapy substances for NFZ (PLN m), 2009
64. Possible change to the business model of pharmaceutical companies as a result of the coming into force the Reimbursement Act in Poland, 2012
65. Market shares of largest players on the pharmaceutical wholesale market in Poland, by sales to pharmacies, Q3 2010
66. Neuca group sales revenues (PLN m) and y-o-y change in Poland, 2003-Q3 2010
67. Sales structure of Neuca in Poland, by subsidiaries, Q1-Q3 2010
68. Neuca net profit (PLN m) and y-o-y change in Poland, 2003-Q3 2010
69. Farmacol group sales revenues (PLN m) and y-o-y change in Poland, 2004-Q3 2010
70. Structure of the Farmacol Group’s sales in Poland, 2009
71. Farmacol net profit (PLN m) and y-o-y change in Poland, 2004-Q3 2010
72. PGF group sales revenues (PLN m) and y-o-y change, 2001-2010
73. Sales structure of the PGF group, by division, 2010
74. PGF net profit (PLN m) and y-o-y change, 2001-2010
75. OPDF shareholder structure in Poland, 2009
76. Hurtap sales revenues and net profit in Poland (PLN m), 2006-2009
77. Intra sales revenues and net profit in Poland (PLN m), 2006-2008
78. Medicare sales revenues and net profit in Poland (PLN m), 2006-2008
79. Lubfarm revenues and net profit in Poland (PLN m), 2006-2008
80. Preska revenues and net profit/loss in Poland (PLN m), 2005-2007
81. ACP Pharma wholesale revenues (PLN m) and y-o-y change in Poland, 2005-2010
82. The structure of ACP Pharma’s sales in Poland, 2010
83. Number of pharmacies and pharmacy outlets in Poland (’000), 1990-May 2010
84. The number of pharmacies owned by pharmacy chains in Poland, Q3 2010
85. Selected largest pharmacy chains in Poland by number of outlets, March 2011
86. The number of franchise, own and partner pharmacies of the Dbam o Zdrowie chain in Poland, end of 2010
87. Pharmacies belonging to Farmacol in Poland, by name, March 2011
88. ACP Pharma retail sales revenues in Poland (PLN m) and y-o-y change, 2005-2010
89. Revenues and net result of BRL Center in Poland (PLN m), 2004-2008
90. Euro Apteki sales revenues and net profit/loss in Poland (PLN m), 2003-2008
91. Most popular internet pharmacies in Poland, by numbers of real users (‘000), December 2010
92. NFZ’s net financial result in Poland, 2004-2009
93. Debt due from independent public healthcare centres in Poland (PLN bn), Q4 2003-Q4 2010
94. Total debt of independent healthcare centres in Poland (PLN bn), Q4 2003-Q4 2010
95. Number of public and non-public hospitals in Poland, 2001-2009

List of tables

1. Sales value of top-15 therapeutic classes in Poland, July 2008-August 2009
2. Top 10 best-selling drugs in Poland, by value (PLN m), 2009
3. Leading generics marketed by leading generic companies in Poland, 2009
4. Top 5 best-selling APIs in Poland, by value (PLN m), 2010
5. Top 10 leading pharmaceutical companies on the Polish pharmaceutical market, by value market share, 2009
6. Tasks of Economic Commission in Poland according to draft Reimbursement Act, 2011
7. Example of pricing in Poland: single substance reference price group, 2010
8. Example of pricing in Poland: multisource reference price group, 2010
9. Example of pricing in Poland: multisource reference price group, 2010
10. Average MSPs (PLN) of packs of original prescription brands and generics in Poland, 2004-March 2011
11. Official retail margins for reimbursed drugs in Poland, 2011
12. Planned official retail margins for reimbursed drugs in Poland, 2011
13. Maximum hospital purchase drug prices in Poland, 2005 list
14. Maximum hospital purchase drug prices, 2006 update
15. Breakdown of market by co-payment type in Poland, chronic disease drugs, January 2010
16. Breakdown of market by co-payment type in Poland, non-chronic disease drugs, January 2010
17. Five pharmaceutical substances generating highest reimbursement costs in Poland, 2009
18. High cost drugs reimbursed under therapeutic programmes in Poland, 2009
19. NMEs added to the reimbursement list in Poland, July 2006-December 2010
20. Net changes to the Polish reimbursement list, 2002-August 2009
21. Atorvastatin 20mg x 30 tablets: impact of December 2009 reimbursement list update in Poland
22. Most important proposed changes in draft Reimbursement Act in Poland, 2011
23. Impact of changes proposed in draft Reimbursement Act on business activities of pharmaceutical companies in Poland, 2011
24. Public and private health care expenditure in Poland, 2007-2008
25. Costs of health care services for the insured covered by the National Health Fund in Poland (‘000), 2008-2011
26. State budget expenditure on health care according to the selected budget chapters in Poland (‘000), 2008-2009
27. Local self-government budget expenditure on health care in Poland (‘000), 2009
28. Registered medical personnel in Poland, 2001-2009
29. Medical personnel employed at healthcare facilities in Poland, 2001-2009
30. Specialists employed at healthcare facilities in Poland, 2006-2009
31. Medical practises registered in chambers of physicians, dentists and midwives in Poland, 2008-2009
32. Out-patient health care institutions in Poland, 2008-2009
33. Number of healthcare centres (ZOZ) and outpatient assistance in Poland, 2000-2009
34. Number of beds and hospitalised in general hospitals in Poland, 2007-2009
35. Average gross monthly remuneration in health care in Poland (PLN), 2010
36. Poles’ monthly healthcare spending (PLN per capita), 2008
37. Poles’ monthly healthcare spending (PLN per capita), 2009
38. Reimbursement status of chronic disease treatments in Poland, 2011

ACP Pharma
Abbott Laboratories
Actavis
Adamed
Allergan
Amgen
Bioton
Boehringer Ingelheim
Farmacol
GlaxoSmithKline
Hurtap
ICN Polfa Rzeszów
Merck&Co
MSD
Neuca
Novarti
Novo Nordisk
Pfizer
PGF
Polfa Warszaw
Polpharma
Polski Holding Farmaceutyczny
Roche
Sandoz
Sanofi-Aventis
Servier
Teva
US Pharmacia
Valeant Pharmaceuticals

and more...